Lisinopril is an angiotensin converting enzyme inhibitor (ACEI), e ective in lowering blood pressure in all grades of essential and renovascular hypertension. YoYo Cleanser Bitters is a liquid oral herbal medication reported to be bene cial in the management of illnesses such as diabetes, hypertension, and obesity, and for the general well-being of the body. The use of herbal bitters like YoYo Bitters is high in Nigeria, especially among patients with chronic illnesses like hypertension and diabetes. The aim of the study was to determine the e ect of YoYo Bitters on the dissolution pro le of lisinopril tablets.
INTRODUCTION

Y
oYo Bitters is an herbal oral preparation popularly used in Southwest Nigeria. It is made from a blend of various parts of plants such as Aloe vera, Cinnamum aromaticum, Citrus aurantifolia, Acinos arvensis, and Chenopodium murale. It is said to be effective in the prevention of kidney and bladder infections. It is also claimed to help to normalize intestinal movement, regulate blood pressure, facilitate digestion, and prevent disorders like ulcers, gastritis, insomnia, stress, depression, and control of body weight (1) .
Preliminary research carried out in some community pharmacies in Lagos, Nigeria, showed that the rate at which bitters are stocked is high, and YoYo Bitters is one of the fast-moving bitters. The high demand in pharmacies occurs especially among patients with chronic diseases owing to the bene cial e ects reported by the manufacturer through intensive advertisement of the product and the claim that hypertensive patients would bene t from its daily use (2) .
Lisinopril is a dicarboxyl-containing angiotensinconverting enzyme inhibitor (ACEI). It has therapeutic uses in hypertension, left ventricular systolic dysfunction, acute myocardial infarction, congestive heart disease, chronic renal failure, renoprotection in diabetic nephropathy, and in patients at high risk of cardiovascular events (3). ACEIs like lisinopril improve endothelial function and reduce cardiovascular events more than other antihypertensive drug (3). Lisinopril has a good tolerability pro le (4) . Economic studies suggest that lisinopril is cost-saving compared with other ACEIs in some markets (5) . This may also be responsible for its increased use among hypertensive patients. Herb-drug interaction refers to the possibility of an herbal drug altering the bioavailability or clinical e ectiveness of a conventional drug when given concurrently. The net result may be an increase or decrease in the e ect of the drugs (6) . Coadministration of herbal medicines with orthodox drugs increases the possibilities of herb-drug interaction. Ginkgo biloba was reported (7) to cause bleeding with warfarin or acetylsalicylic acid. Hypericum perforatum (St. John's wort) has been reported (8) to decrease plasma concentrations of cyclosporine, dx.doi.org/10.14227/DT220115P6 *Corresponding author. e-mail: olubunmicares@yahoo.com tacrolimus, oral contraceptives, simvastatin, nifedipine, and verapamil.
It was reported in a study carried out in Nigeria (1) that YoYo Bitters inhibited the metabolism of paracetamol tablets in some human subjects. The use of herbal medications is increasing in Nigeria (9) . The use is common among patients that are on some medications used for the treatment of chronic diseases like hypertension and diabetes (10, 11) .
Both the incidence of hypertension and the use of herbal bitters are increasing in the general population, setting the stage for potential coadministration of antihypertensives and herbal remedies. The Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of high blood pressure (JNC 7) has advocated the use of ACEIs as a rst line in the management of hypertension (12) . For this reason, a cost-e ective ACEI like lisinopril is a likely choice, and the coadministration of lisinopril with YoYo Bitters is likely to occur.
Drugs must be available in the systemic circulation to be e cacious. The process of bioavailability involves two stages: dissolution and absorption/permeability. Any interruption in the process of dissolution could a ect the amount of the active drug in the systemic circulation, thereby altering the clinical e ect of the drug.
In vitro dissolution measures the rate and extent of drug dissolution or release. It determines the cumulative amount of drug that goes into solution as a function of time (13) . It is a useful test to forecast the in vivo performance of a drug product, and it potentially reduces the number of bioavailability/bioequivalence studies required (14) .
Since there is a paucity of data concerning the e ect of herbal bitters on the dissolution of lisinopril tablets, it is therefore necessary to investigate the e ect that YoYo Bitters may have on the dissolution pro le of lisinopril tablets.
MATERIALS AND METHODS
Materials
Lisinopril dihydrate 100% (USP) and diclofenac (USP) Reference Standards were obtained from the USP. Lisinopril tablets 10-mg (Zestril) and YoYo Bitters (Table 1) were bought from a registered pharmacy in Lagos, Nigeria. Concentrated hydrochloric acid (Sigma-Aldrich, Germany), glacial acetic acid (Sigma-Aldrich, Germany), potassium dihydrogen phosphate (JT Baker, USA), orthophosphoric acid 85% (Merck, Germany), sodium hydroxide pellets (JT Baker, USA), ammonium acetate (Lab Tech Chemicals), hexane-1-sulphonic acid sodium salt (ROMIL-SpR, GB), methanol HPLC grade 99% (Lichrosolv), and acetonitrile HPLC grade 99% (Lichrosolv) were obtained.
Physicochemical Characterization of Lisinopril Tablets and YoYo Bitters
Weight uniformity, hardness, friability, and assay of lisinopril tablets were carried out according to the British Pharmacopoeia (BP) method (15) .
The color of YoYo Bitters was determined by visual inspection of the liquid preparation and recorded. The taste and pH of the herbal product was also determined. 
In Vitro Dissolution Test
In vitro dissolution was carried out using tablet dissolution test USP Apparatus 2 (paddle). The dissolution tests were carried out in three media: 0.1 N HCl at pH 1.2, pH 4.5 acetate bu er, and pH 6.8 phosphate bu er. A volume of 900 mL of the di erent dissolution media was used, and the temperature was maintained at 37 ± 0.5 °C at a xed speed of 50 rpm. Twelve units were tested according to FDA and USP speci cations. A tablet was put in each vessel, and the equipment was operated for one hour. Sample aliquots of 5 mL were taken at 5, 10, 15, 30, 45, and 60 min and replaced with 5 mL of fresh dissolution medium to maintain sink conditions. Each of the withdrawn samples was ltered with the aid of a 0.45-µm syringe lter. The ltrate was then analyzed by HPLC-UV. The experiment was carried out in two parts, lisinopril tablets alone and lisinopril tablets with YoYo Bitters in the three di erent media.
Preparation of Dissolution Media
In preparing 1000 mL of the dissolution medium, 300 mL of YoYo Bitters was measured in a 1000mL measuring cylinder, and 0.1 N HCl was added to make 1 L of the dissolution medium. For the dissolution test, 900 mL of medium was used, and part of the remaining volume was used to maintain sink conditions. The same procedure was repeated for acetate bu er and phosphate bu er. The 0.1 N HCl and acetate bu er were prepared according to the BP method (15), while phosphate bu er was prepared according to USP (16).
High Performance Liquid Chromatography
The chromatographic procedure was carried out using a stainless steel Eclipse SB-C18, 4.6 × 150 mm, 5-µm column (Agilent) maintained at 40 °C. The mobile phase was prepared by adding 200 mL of acetonitrile to 800 mL of a 0.408% w/v solution of anhydrous potassium dihydrogen orthophosphate adjusted to pH 2.0 with orthophosphoric acid containing 0.125% w/v of sodium hexanesulphonate. The mobile phase was ltered with the aid of a 0.45-µm Millipore lter. The ow rate of the mobile phase was 1 mL/ min. The detector wavelength was 215 nm. The mobile phase was passed through the column for at least 30 min before starting the chromatography.
Data Analysis
GraphPad Prism 6.0 software (La Jolla, CA) was used in the analysis of the data using paired t-test at level of signi cance of p < 0.05.
RESULTS
Lisinopril tablet is a round, light pink tablet embossed with the shape of a heart and ZESTRIL 10. Table 2 shows the physicochemical parameters of lisinopril tablets. Table  3 represents the physical properties of YoYo Bitters. Table 4 lists the percentages of lisinopril released at pH 1.2, 4.5, and 6.8. Figures 1-3 show the dissolution pro les of lisinopril tablets alone and in the presence of YoYo Bitters in the three media. 
DISCUSSION
Dissolution of a drug in solid dosage form into an aqueous medium is critical to its absorption, which has an impact on its bioavailability and hence therapeutic e cacy. Variables such as uniformity of weight, hardness, friability, and percentage purity also play important roles in e cient release of the active ingredient of the drug for systemic absorption (17) . These parameters were therefore evaluated before carrying out the dissolution studies. The results conformed to the speci cations in the BP (15). The pH of YoYo Bitters is 2.9, thus it is acidic in nature. This could be because of some of its constituents such as Cinnamon aromaticum, Citrus aurantifolia, and Acinos arvensis. Cinnamon aromaticum contains cinnamic acid, Citrus aurantifolia contains citric acid and ascorbic acid, while Acinos arvensis contains Linolenic acid (19) .
In this study, at pH 1.2, which mimics acidic condition of the stomach, the percentage release of lisinopril alone without YoYo Bitters did not conform to the dissolution monograph of lisinopril as speci ed in BP 2007, which states that the amount of lisinopril released should not be less than 85% of the stated amount at 30 min. This means that it failed the dissolution test at this pH. In the presence of YoYo Bitters, the percentage release of lisinopril increased. The paired t-test of percentage release of lisinopril tablets alone and lisinopril tablets with YoYo Bitters showed a signi cant di erence (p = 0.0015). YoYo Bitters could have enhanced the solubility of lisinopril tablet, thereby aiding the release of lisinopril. An increase in the solubility of a drug increases absorption, which might increase the bioavailability of the drug. An increase in the bioavailability of lisinopril could lead to an increase in the therapeutic concentration, which could have serious clinical implications like hypotension and shock if above the maximum safe concentration.
The percentage release of lisinopril alone at pH 4.5 conformed to the speci cation in the monograph. In the presence of YoYo Bitters, the change in the percentage release of lisinopril was not statistically signi cant (p = 0.1232). This pH mimics the transit between the stomach and small intestine.
At pH 6.8, the percentage release of lisinopril alone also conformed to the speci cation in the monograph. In the presence of YoYo Bitters, the percentage release of lisinopril was lower than the result obtained from lisinopril alone. The statistical test of the di erence showed it to be statistically signi cant (p = 0.0140). HPLC analysis of YoYo Bitters eluted a number of substances that could not be identi ed. This is not surprising as it is a mixture of about ve herbs. These constituents could have interacted with the process of dissolution at this stage.
A pH of 6.8 mimics intestinal conditions where absorption takes place; therefore, any dissolution observed here is critical to the absorption or bioavailability of the drug. Decrease in dissolution of lisinopril tablets could lead to decrease in absorption of the active ingredient and in turn bioavailability of the drug. Decreased bioavailability could lead to therapeutic failure, which could lead to uncontrolled hypertension posing a threat to some organs of the body like the heart, eyes, brain, and kidneys, thereby compromising positive clinical outcomes in patients taking such medications. A report (20) states that herbs like Aloe vera and other anthraquinone-containing herbs could inhibit absorption of conventional drugs as a result of chelation or formation of insoluble complexes with the drugs.
Concurrent use of YoYo Bitters and lisinopril tablets could increase the potential for herb-drug interaction, which may have signi cant clinical consequences. Health care professionals therefore have the responsibility of educating patients about this behavior. Coadministration of an herbal product like YoYo Bitters could a ect the dissolution of lisinopril tablets in various ways, either by increasing or decreasing the percentage release of the drug depending on the pH of the absorption site. Coadministration of these two medications should therefore be done with great caution to prevent serious clinical consequences.
CONCLUSION
YoYo Bitters signi cantly increased the dissolution of lisinopril tablets at pH 1.2. There was no statistically signi cant di erence between the dissolution of lisinopril tablets with and without YoYo Bitters at pH 4.5. The dissolution of lisinopril tablets decreased signi cantly in the presence of YoYo Bitters at pH 6.8.
